

## Special Issue

# Recent Advances in Diagnosis, Treatment and Prognosis of Giant Cell Tumor of the Bone

### Message from the Guest Editor

Giant cell tumor (GCT) of the bone is a locally aggressive and rarely metastasizing primary bone tumor. The controversial treatment is decided by the balance between an adequate surgical margin and sufficient adjacent joint function. Curettage with a high-speed burr and local adjuvants is the most indicated treatment for active lesions, but with a high local recurrence rate. Conversely, en bloc resection for aggressive lesions have lower local recurrence rates, but increased morbidity and possible functional impairment. We would like to invite physicians and researchers involved in this field to contribute observations and results to this Special Issue.

### Guest Editor

Dr. Laura Campanacci

Orthopaedic Oncology Unit, IRCCS Rizzoli Orthopaedic Institute, Bologna, Italy

### Deadline for manuscript submissions

closed (30 June 2024)



## Current Oncology

---

an Open Access Journal  
by MDPI

---

Impact Factor 2.8  
CiteScore 3.3  
Indexed in PubMed



[mdpi.com/si/163789](https://mdpi.com/si/163789)

*Current Oncology*  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[currentoncology@mdpi.com](mailto:currentoncology@mdpi.com)

[mdpi.com/journal/  
currentoncology](https://mdpi.com/journal/currentoncology)





# Current Oncology

---

an Open Access Journal  
by MDPI

---

Impact Factor 2.8  
CiteScore 3.3  
Indexed in PubMed



[mdpi.com/journal/  
currentcol](https://mdpi.com/journal/currentcol)



## About the Journal

### Message from the Editor-in-Chief

I am honored and enthusiastic to serve as incoming Editor-in-Chief of *Current Oncology*. Since its establishment in 1994, *Current Oncology* has been playing an important role in the advancement of cancer care by disseminating new knowledge in the cancer care continuum. *Current Oncology* is affiliated with several key cancer societies and provides a global platform to share scientific progress in oncology. We strive for high standards and work together to maintain a rigorous and unbiased peer review process to publish high-quality articles. We have an outstanding editorial team which is committed to the success of *Current Oncology*.

---

### Editor-in-Chief

Prof. Dr. Shahid Ahmed

1. College of Medicine, University of Saskatchewan, Saskatoon, SK S7N5E5, Canada
2. Saskatchewan Cancer Agency, Saskatoon Cancer Center, Saskatoon, SK S7N5H5, Canada

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility

: indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology)